A Phase 1a "Window Trial" on Cannabidiol (CBD) for Breast Cancer Primary Tumors

Sponsor:

MUSC

Sponsor Study ID:

103565

CTO #:

103565

NCT Number:

NCT06148038

Phase:

N/A

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Breast; Larynx; Lip, Oral Cavity and Pharynx

Study Objectives:

To determine whether oral administration of cannabidiol (CBD) causes biological changes related to cell proliferation (using Ki67 expression as a marker) in primary tumors of breast cancer patients.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)